Peter Y F Zeng
Overview
Explore the profile of Peter Y F Zeng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeng P, Lin R, Fung K, Khan H, Cecchini M, Woo E, et al.
EBioMedicine
. 2025 Mar;
114:105631.
PMID: 40048848
Background: The larynx consists of the supraglottis, glottis, and subglottis and each differ in tissue composition, lymphatic drainage, ability to counter infections, and response to injuries. However, the cellular mechanisms...
2.
Dawson A, Karimi A, Shaikh M, Gazala W, Zeng P, Ryan S, et al.
Oral Oncol
. 2024 Oct;
159:107061.
PMID: 39357386
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type worldwide. In recent years, there has been an increase in the rate of HNSCC cases attributed...
3.
Danko B, Hess J, Unger K, Samaga D, Walz C, Walch A, et al.
NPJ Precis Oncol
. 2024 May;
8(1):116.
PMID: 38783045
Head and Neck Squamous Cell Carcinoma (HNSCC) is a heterogeneous malignancy that remains a significant challenge in clinical management due to frequent treatment failures and pronounced therapy resistance. While metabolic...
4.
Zeng P, Prokopec S, Lai S, Pinto N, Chan-Seng-Yue M, Clifton-Bligh R, et al.
Cell Rep
. 2024 Feb;
43(3):113826.
PMID: 38412093
Anaplastic thyroid carcinoma is arguably the most lethal human malignancy. It often co-occurs with differentiated thyroid cancers, yet the molecular origins of its aggressivity are unknown. We sequenced tumor DNA...
5.
Gameiro S, Salnikov M, Zeng P, Barrett J, Nichols A, Mymryk J
Viruses
. 2023 Dec;
15(12).
PMID: 38140652
Human papillomavirus (HPV) is the major causative agent for cervical and many head and neck cancers (HNCs). HPVs randomly acquire single nucleotide polymorphisms (SNPs) that may become established via positive...
6.
Laxague F, Zeng P, Zabihi D, Fnais N, Alshahrani M, Fung K, et al.
Head Neck
. 2023 Dec;
46(3):503-512.
PMID: 38100227
Background: We aimed to analyze and compare the timing and patterns of treatment failure, and survival after progression between HPV-positive (HPV+) and HPV-negative (HPV-) patients undergoing chemoradiation for oropharyngeal squamous...
7.
Kim H, Zeng P, Cecchini M, Shaikh M, Laxague F, Deng X, et al.
Head Neck
. 2023 Dec;
46(2):353-366.
PMID: 38059331
Background: Adverse pathological features following surgery in head and neck squamous cell carcinoma (HNSCC) are strongly associated with survival and guide adjuvant therapy. We investigated molecular changes associated with these...
8.
Shaikh M, Dawson A, Prokopec S, Barrett J, Zeng P, Khan M, et al.
Oral Oncol
. 2023 Oct;
146:106580.
PMID: 37778229
Objectives: Although human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients typically experience excellent survival, 15-20 % of patients recur after treatment with chemotherapy and radiation. Therefore, there is...
9.
Shin A, Tesfagiorgis Y, Larsen F, Derouet M, Zeng P, Good H, et al.
Gastroenterology
. 2023 Jan;
164(4):593-609.e13.
PMID: 36634827
Background & Aims: Colorectal cancer is a leading cause of cancer death, and a major risk factor is chronic inflammation. Despite the link between colitis and cancer, the mechanism by...
10.
Zeng P, Cecchini M, Barrett J, Shammas-Toma M, De Cecco L, Serafini M, et al.
EBioMedicine
. 2022 Nov;
86:104373.
PMID: 36442320
Background: There is significant interest in treatment de-escalation for human papillomavirus-associated (HPV) oropharyngeal squamous cell carcinoma (OPSCC) patients given the generally favourable prognosis. However, 15-30% of patients recur after primary...